Wockhardt Ltd 2019 AR2
The report highlights Wockhardt Limited's performance and strategic focus on Research & Development, particularly in developing New Chemical Entities (NCEs) to combat Antimicrobial Resistance. During the fiscal year 2018-19, the company filed 95 patents and was granted 66, expanding its cumulative patent base to 3,132 filings. Wockhardt also established its first manufacturing facility in the Middle East (Dubai) dedicated to NCEs. Additionally, the company continued its social initiatives through the Wockhardt Foundation, touching over 121 million lives through healthcare, education, and sanitation programs.
Company: Wockhardt Ltd
Sector: Manufacturing
Country: India
Year: 2019
Type: AR2
Pages: 196
Back to company
Wockhardt Ltd
Annual Report
The report highlights Wockhardt Limited's performance and strategic focus on Research & Development, particularly in developing New Chemical Entities (NCEs) to combat Antimicrobial Resistance. During the fiscal year 2018-19, the company filed 95 patents and was granted 66, expanding its cumulative patent base to 3,132 filings. Wockhardt also established its first manufacturing facility in the Middle East (Dubai) dedicated to NCEs. Additionally, the company continued its social initiatives through the Wockhardt Foundation, touching over 121 million lives through healthcare, education, and sanitation programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees